QIAGEN Announces Supply Agreement with Roche Molecular Systems to Provide AmpliLute Media Sample Preparation Kits
Feb 09 2005

QIAGEN Announces Supply Agreement with Roche Molecular Systems to Provide AmpliLute Media Sample Preparation Kits

Venlo, the Netherlands, February 09, 2005: QIAGEN GmbH, a wholly-owned subsidiary of QIAGEN N.V. (Nasdaq: QGENF, Frankfurt, Prime Standard: QIA) today announced that they have entered into a manufacturing and supply agreement with Roche Molecular Systems, Pleasanton, California, a unit of Roche Diagnostics Basel, Switzerland, who will market QIAGEN's media sample preparation kits under their AmpliLute trademark.

This customized kit will incorporate a specific version of QIAGEN's well-established QIAamp® technology to purify DNA from specimens stored in liquid cytology media. QIAGEN's proprietary nucleic acid sample preparation and handling technologies provide high reliability and efficiency in both DNA and RNA separation and purification for molecular diagnostics applications.

"We are very pleased that Roche Diagnostics has selected QIAGEN nucleic acid purification kits as a front-end preparation solution to their amplification and detection procedure," said Dr. Frank Krieg-Schneider, Executive Director Strategic Alliances at QIAGEN. "Roche is a leader in molecular diagnostics and their PCR tests are considered to be some of the most highly sensitive and efficient molecular diagnostic testing products available in the marketplace. Efficient extraction and purification of target nucleic acids are elements to sensitive and reliable nucleic acid testing."



QIAGEN N.V., a Netherlands holding company with subsidiaries in Germany, the United States, Japan, the United Kingdom, Switzerland, France, Italy, Australia, Norway, Austria, Canada, and the Netherlands believes it is the world's leading provider of innovative enabling technologies and products for the separation, purification and handling of nucleic acids and proteins. QIAGEN has developed a comprehensive portfolio of more than 320 proprietary, consumable products for nucleic acid and protein separation, purification and handling, nucleic acid amplification, as well as automated instrumentation, synthetic nucleic acid products and related services. QIAGEN's products are sold in more than 42 countries throughout the world to academic research markets and to leading pharmaceutical and biotechnology companies. In addition, QIAGEN is positioning its products for sale into developing commercial markets, including DNA sequencing and genomics, nucleic acid-based molecular diagnostics, and genetic vaccination and gene therapy. QIAGEN employs approximately 1,400 people worldwide. Further information on QIAGEN can be found at http://www.qiagen.com/.


Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations and risks of dependency on logistics), variability of operating results, the commercial development of the DNA sequencing, genomics and proteomics markets, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's, products (including seasonal fluctuations), difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors, market acceptance of QIAGEN's new products and the integration of acquisitions of technologies and businesses. For further information, refer to the discussion in reports that QIAGEN has filed with the U.S. Securities and Exchange Commission (SEC).






Phone: +49 2103 29 11710

Fax: +49 2103 29 21710

Email: ir@qiagen.com


Share this page